About CollaGenex
CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on developing and marketing proprietary, innovative medical therapies to the dermatology market.
CollaGenex's has a highly-experienced 80-person sales force that is targeting 5,600 dermatologists. In July 2006, CollaGenex launched Oracea® (Doxycycline, USP) Capsules 40 mg*, the first FDA-approved systemic product for the treatment of rosacea. The Company also markets Alcortin® (1% iodoquinol and 2% hydrocortisone), a prescription topical antifungal steroid combination, and Novacort® (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription topical steroid and anesthetic. Alcortin and Novacort are marketed by the Company under a Promotion and Cooperation agreement with Primus Pharmaceuticals, Inc.
The Company has a pipeline of innovative product candidates with possible applications in dermatology and other disease states. CollaGenex is conducting Phase II clinical trials to evaluate COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea. CollaGenex recently acquired the rights to develop and commercialize becocalcidiol, a patented Vitamin D analogue developed by QuatRx Pharmaceuticals Company, and it is currently in Phase II clinical trials for the topical treatment of mild to moderate psoriasis.
CollaGenex plans to leverage its technology platforms to develop a range of topical dermatological products with enhanced pharmacologic and cosmetic properties. Based on research that has shown compounds can be created by chemically modifying certain tetracyclines and that these new compounds have properties that may make them effective in treating diseases involving inflammation and/or destruction of the body's connective tissues, CollaGenex is evaluating various chemically modified tetracyclines (so called "IMPACS"™ compounds because they are Inhibitors of Multiple Proteases And CytokineS) to assess whether they are safe and effective in these applications. In addition, CollaGenex has acquired the SansRosa™ technology, which consists of a class of compounds that have shown promise in reducing the redness associated with rosacea; becocalcidiol, a patented Vitamin D analogue; and the Restoraderm® technology, a unique, proprietary dermal drug delivery system.
Periostat®, Restoraderm® and Oracea® are registered trademarks and IMPACS™ and SansRosa™ are trademarks of CollaGenex Pharmaceuticals, Inc.
Novacort® and Alcortin® are trademarks of Primus Pharmaceuticals, Inc.
All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceuticals, Inc. or any of our subsidiaries.
* 30 mg Immediate Release and 10 mg Delayed Release beads.
© 2008 Collagenex Pharmaceuticals, All Rights Reserved.